AHA 23: Nicotinamide Riboside in PAD for Improved Walking

Описание: Dr Mary McDermott (Northwestern University, US) joins us to summarize the key findings from a randomized clinical trial investigating whether nicotinamide riboside (NR) can enhance walking performance in patients with peripheral artery disease (PAD).

Investigators randomized 90 patients with ABI ≤ 0.90 at baseline into three groups - one receiving 100mg daily NR with 125mg resveratrol, one receiving 100mg daily NR alone, and one receiving placebo.

The results showed that NR significantly improved six-minute walk distance and treadmill walking time in PAD. Resveratrol did not enhance the effects of NR, with similar findings between patients who had received NR and resveratrol and NR alone. Despite this, it must be noted that there was a high-non-adherence rate in the NR and resveratrol group.

Questions:
-What is the rationale for NR supplementation in patients with PAD?
-What was the study design and outcome measures?
-What are the baseline characteristics of the randomized patients?
-What is the data presented at AHA 2023?
-Were there any unexpected or surprising results in the trial?
-What are the take-home messages?
-What are the next steps?

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

This is an independent interview conducted by Radcliffe Cardiology.

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/?...

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:   / radcliffecardiology  
Follow us on X: https://x.com/radcliffeCARDIO